A detailed history of Qube Research & Technologies LTD transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 27,941 shares of KROS stock, worth $1.58 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
27,941
Previous 31,235 10.55%
Holding current value
$1.58 Million
Previous $1.43 Million 13.67%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$41.68 - $58.07 $137,293 - $191,282
-3,294 Reduced 10.55%
27,941 $1.62 Million
Q2 2024

Aug 14, 2024

BUY
$44.58 - $66.89 $1.29 Million - $1.94 Million
28,973 Added 1280.86%
31,235 $1.43 Million
Q1 2024

May 14, 2024

SELL
$41.26 - $70.48 $1.33 Million - $2.28 Million
-32,280 Reduced 93.45%
2,262 $149,000
Q4 2023

Feb 13, 2024

BUY
$27.12 - $41.05 $693,838 - $1.05 Million
25,584 Added 285.6%
34,542 $1.37 Million
Q3 2023

Nov 13, 2023

SELL
$31.57 - $43.02 $564,471 - $769,197
-17,880 Reduced 66.62%
8,958 $285,000
Q2 2023

Aug 14, 2023

SELL
$37.26 - $51.01 $401,401 - $549,530
-10,773 Reduced 28.64%
26,838 $1.08 Million
Q1 2023

May 15, 2023

BUY
$41.44 - $59.32 $1.02 Million - $1.46 Million
24,631 Added 189.76%
37,611 $1.61 Million
Q4 2022

Feb 14, 2023

SELL
$39.45 - $51.77 $356,470 - $467,793
-9,036 Reduced 41.04%
12,980 $623,000
Q3 2022

Nov 14, 2022

SELL
$27.8 - $40.12 $890,017 - $1.28 Million
-32,015 Reduced 59.25%
22,016 $828,000
Q2 2022

Aug 15, 2022

BUY
$26.03 - $67.04 $1.41 Million - $3.62 Million
54,031 New
54,031 $1.49 Million

Others Institutions Holding KROS

About Keros Therapeutics, Inc.


  • Ticker KROS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,757,000
  • Market Cap $1.46B
  • Description
  • Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...
More about KROS
Track This Portfolio

Track Qube Research & Technologies LTD Portfolio

Follow Qube Research & Technologies LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.